PRESS RELEASE published on 08/22/2024 at 18:00, 2 years ago Inside Information / Other news releases ABIONYX Pharma reports €2.4m sales and €5.3m cash position for H1 2024, focused on innovative therapies. Raised €3.4m for sepsis program in the US Sales Cash Position Innovative Therapies ABIONYX Pharma Sepsis
BRIEF published on 07/01/2024 at 09:27, 2 years 1 month ago ABIONYX Successfully Completes €3.4 Million Capital Increase Capital Increase Biotech Shares And Warrants ABIONYX Sepsis Development
BRIEF published on 07/01/2024 at 09:27, 2 years 1 month ago ABIONYX finalise avec succès une augmentation de capital de 3,4 millions d'euros Augmentation De Capital Actions Et Bons De Souscription Biotechnologies ABIONYX Développement De La Septicémie
PRESS RELEASE published on 07/01/2024 at 09:22, 2 years 1 month ago Inside Information / Other news releases ABIONYX successfully completes a capital increase of c.€3.4 million through the issuance of shares with warrants. The fundraising aims to strengthen the company's cash position for its development in sepsis and the United States Fundraising Capital Increase Sepsis ABIONYX Shares With Warrants
BRIEF published on 06/27/2024 at 19:27, 2 years 2 months ago ABIONYX Pharma Achieves Unanimous Approval at Combined General Meeting Shareholders Biotech General Meeting Resolutions ABIONYX Pharma
BRIEF published on 06/27/2024 at 19:27, 2 years 2 months ago ABIONYX Pharma obtient l'approbation unanime de l'Assemblée Générale Mixte Actionnaires Assemblée Générale Resolutions Biotechnologies ABIONYX Pharma
PRESS RELEASE published on 06/27/2024 at 19:22, 2 years 2 months ago Inside Information / Other news releases ABIONYX Pharma announces unanimous approval of all resolutions at its Combined General Meeting. Shareholders renew mandates and approve buyback program Shareholders Buyback Program Renewal Combined General Meeting ABIONYX Pharma
PRESS RELEASE published on 06/27/2024 at 19:22, 2 years 2 months ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce l'approbation unanime des résolutions lors de son Assemblée Générale Mixte. Renouvellement des mandats et programmes approuvés Assemblée Générale Mixte Mandats Renouvelés ABIONYX Pharma Approbation Unanime Programmes Approuvés
BRIEF published on 06/19/2024 at 21:20, 2 years 2 months ago ABIONYX annonce une augmentation de capital sans droit préférentiel de souscription Biotechnologie Actions Augmentation De Capital États-Unis Sepsis
BRIEF published on 06/19/2024 at 21:20, 2 years 2 months ago ABIONYX announces a capital increase without preferential subscription rights Biotechnology Actions United States Increase In Capital Sepsis
Published on 08/28/2026 at 14:00, 4 hours 48 minutes ago Lobe Sciences Expands Leadership Team with New CFO Appointment
Published on 08/28/2026 at 13:00, 5 hours 48 minutes ago Abasca Files NI 43-101 Technical Report, Commences Summer Exploration Program at Loki and Elects to File Semi-annual Interim Financial Statements and Related MD&A
Published on 08/28/2026 at 08:05, 10 hours 43 minutes ago Caledonia Mining Corporation Plc: Maiden Mineral Resource Estimate at Motapa 379,000 oz Measured and Indicated; 131,000 oz Inferred
Published on 08/28/2026 at 08:05, 10 hours 43 minutes ago Tocvan Announces New Surface Mineralization in Several Zones at Gran Pilar Gold-Silver Project
Published on 08/28/2026 at 08:00, 10 hours 48 minutes ago Caledonia Mining Corporation Plc: Blanket Mine Underground Measured and Indicated Mineral Resources Estimate Increases by 22% to 2.18 Million Ounces and Declaration of a Surface Mineral Resource Estimate
Published on 08/28/2026 at 18:01, 46 minutes ago CPI Europe announces unaudited results for the first half of 2026
Published on 08/28/2026 at 18:00, 48 minutes ago Highlight Event and Entertainment AG publishes results for the first half of 2026
Published on 08/28/2026 at 18:00, 48 minutes ago Investis successfully issues a fixed rate bond of CHF 100 million
Published on 08/28/2026 at 18:00, 48 minutes ago Investis émet avec succès un emprunt obligataire à taux fixe d’un volume de CHF 100 millions
